Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 13–24 of 411 articles
- Check methods and identity
What newer muscle imaging adds to the ACE-083 story
ACE-083 is a larger engineered fusion protein made from modified follistatin and the Fc region of a human antibody. It was designed to capture signals that restrict muscle growth near the muscle under study.
ACE-0832 sources (2022, 2026)
- Interpret the evidence
Why bigger muscles did not settle the FSHD trial
ACE-083 is an investigational fusion protein based on follistatin. It was engineered to sequester myostatin, activins and other signals around a targeted muscle.
ACE-0831 source (2022)
- Explore study findings
What the Charcot-Marie-Tooth trial learned from the ankle
ACE-083 is a larger engineered protein that combines a form of follistatin with an antibody Fc region. It was investigated for local muscle growth.
ACE-0831 source (2022)
- Explore study findings
What healthy volunteers revealed about a local effect
ACE-083 is a larger follistatin-based fusion protein developed to trap signals in the tissue where it was placed. Its 2018 first-in-human study asked how healthy volunteers tolerated it and whether a selected muscle changed in volume.
ACE-0832 sources (2018, 2022)
- Understand the science
How the fusion protein was designed to stay local
ACE-083 is an engineered fusion protein containing human FST291, a form of follistatin, joined to the Fc region of human IgG2. An older 2019 study looked at two kinds of binding that mattered for the design.
ACE-0831 source (2019)
- Explore study findings
What mouse models could reveal about contraction
ACE-083 is a larger engineered follistatin fusion protein built to capture several growth-regulating proteins locally. A 2019 animal study asked whether muscle enlargement after ACE-083 came with a change in the force that the same muscle could produce.
ACE-0832 sources (2019, 2022)
- Explore study findings
What a 2026 study revealed about adipotide’s target
Adipotide is an experimental construct with two linked peptide segments. One was designed to recognize a form of a protein called prohibitin-1 at the surface of blood vessels that supply white fat. The other can trigger programmed cell death after entering a cell.
Adipotide2 sources (2011, 2026)
- Understand the science
How scientists found a peptide that homes to fat blood vessels
Adipotide is an experimental peptide-based construct built around that principle. Its discovery started with a question about location. Could researchers find a sequence that would collect preferentially in the small blood vessels that serve white fat?
Adipotide1 source (2004)
- Check methods and identity
What imaging revealed in the adipotide monkey experiment
Adipotide is an experimental peptide construct designed to reach the blood vessels that supply white fat and trigger the death of some of the cells lining those vessels. An older primate study asked whether changes on the scale corresponded to changes in the amount of fat tissue.
Adipotide1 source (2011)
- Explore study findings
Why the adipotide kidney findings mattered
Adipotide is an investigational two-part peptide construct designed to reach white fat blood vessels and trigger programmed cell death there. The older direct studies illustrate why a report on where a peptide is intended to act belongs alongside observations of which organs actually respond.
Adipotide2 sources (2010–2019)
- Explore study findings
What changed when researchers put the peptide cargo in a nanoparticle
Adipotide connects a fat-vessel-targeting segment directly to a segment that triggers cell death. An older mouse experiment compared this linked design with a delivery particle carrying a similar payload and displaying the targeting peptide on its surface.
Adipotide1 source (2013)
- Understand the science
How to read adipotide’s terminated first-in-human trial
Adipotide, studied under the name prohibitin targeting peptide 1, pairs a fat blood vessel recognition sequence with a cell-killing segment. Its older ClinicalTrials.gov record provides a concrete example of what a registered study can tell a reader when results are unavailable.
Adipotide2 sources (2010–2019)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
